Partland Vistagen Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Partland vistagen therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Partland Vistagen Therapeutics Today - Breaking & Trending Today

VistaGen Therapeutics Announces Pricing of Underwritten Public Offering

VistaGen Therapeutics Announces Pricing of Underwritten Public Offering
VistaGen Therapeutics Announces Pricing of Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the “Common Stock”), and 2,000,000 shares of its Series D convertible preferred stock (“Series D Preferred Stock”) at a public offering price of $21.16 per share. ....

New York , United States , Riverside Plaza , Vistagen Therapeutics Inc , William Blair Company , Exchange Commission , Prospectus Department , Equity Syndicate Prospectus Department , Vistagen Therapeutics , Seriesd Preferred Stock , Common Stock , Seriesd Preferred , William Blair , Looking Statements Certain , Annual Report , Quarterly Report , Contact Mark , Partland Vistagen Therapeutics , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஆற்றங்கரை ப்லாஸ , வில்லியம் பிளேயர் நிறுவனம் , பரிமாற்றம் தரகு , ப்ரோஸ்பெக்டஸ் துறை , பங்கு கூட்டமைப்பு ப்ரோஸ்பெக்டஸ் துறை , பொதுவானது ஸ்டாக் ,

VistaGen Therapeutics Announces Pricing of Underwritten Public Offering

Message :
Required fields
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the “Common Stock”), and 2,000,000 shares of its Series D convertible preferred stock (“Series D Preferred Stock”) at a public offering price of $21.16 per share.
Gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be $100 million. All of the securities in the offering are being sold by VistaGen. ....

New York , United States , Riverside Plaza , Vistagen Therapeutics Inc , Company Contact , William Blair Company , Exchange Commission , Prospectus Department , Equity Syndicate Prospectus Department , Marka Mcpartland Vistagen Therapeutics Inc , Gen Therapeutics , Seriesd Preferred Stock , Common Stock , Seriesd Preferred , William Blair , Annual Report , Quarterly Report , Partland Vistagen Therapeutics , Vistagen Therapeutics , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஆற்றங்கரை ப்லாஸ , நிறுவனம் தொடர்பு , வில்லியம் பிளேயர் நிறுவனம் , பரிமாற்றம் தரகு , ப்ரோஸ்பெக்டஸ் துறை ,